ANTHEM

Anthem Biosciences Limited · NSE · INE0CZ201020 · 272 sessions on record

₹855.75▼ −2.85 · −0.3%from ₹858.60 the session before · 1 Oct 2026 close · NSE end of day

Open: ₹851.50
High: ₹859.75
Low: ₹830.60
Day's range: ₹293.4% of the previous close
VWAP: ₹843.59close +1.4% from it
Volume, shares: 6.5 L0.71× the 20-session average
Turnover, ₹ crore: 55
Trades: 36,00018 shares per trade
Previous close: ₹858.60−2.85 to the close
Price band, next session: ₹770.20 – ₹941.3510% either side of the close · dynamic, widened in 5% steps when hit

Day range86% of the way up

₹830.60₹859.75

52-week range69% of the way up

₹579.15 2 Feb₹977.55 9 Sept

−12% from the high · +48% from the low

Futures and options

No derivatives listed on ANTHEM

Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

272 sessions on file · from 28 Aug

ANTHEM close
Nifty 50, rebased

Session read · latest close: 1 Oct 2026
Close ₹ · day %: ₹855.75▼ −0.3% on the previous close
Against Nifty 50: Nifty −0.9%+0.5 pp difference on the day
Against the averages: below 20 · below 5020-session ₹909.74 (−5.9%) · 50-session ₹878.10 (−2.5%)
Volume: 0.71×the previous 20 sessions · 6.5 L shares
Extremes on the day: none

Quarterly results

consolidated · latest filed 21 Jul, 05:07 pm IST · NSE filings

Revenue ₹418 cr; profit ₹120 cr in the Jun 2026 quarter, consolidated.

Last 2 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session

Quarterly results of ANTHEM on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹	Market on the day
Jun 2026filed 21 Jul	₹418 cr	—	₹120 cr	—	2.11	▼ −1.6%Nifty −0.8% · −0.8 pp
Mar 2026filed 20 May · audited	₹611 cr	—	₹190 cr	—	0.00	▼ −0.9%Nifty +0.2% · −1.0 pp

Fundamentals

consolidated · filings to Jun 2026 · close ₹855.75 on 1 Oct

16 times book value, a 0.47% dividend yield, market cap ₹48,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing

Market cap: ₹48,000 cron 1 Oct · free float ₹14,000 cr
Price to earnings: —fewer than four consecutive quarters filed
Trailing EPS: —fewer than four consecutive quarters filed
Price to book: 16consolidated · balance sheet to Mar 2026
Book value a share: ₹53.99consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity: 0.02borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity: —needs two filed balance sheets
Dividend yield: 0.47%₹4.00 a share in 365 days
Face value: ₹2a share
Shares outstanding: 56 cron 1 Oct

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: —fewer than four consecutive quarters filed
Revenue growth, 12 months: —needs eight consecutive quarters filed
Revenue 3-year CAGR: —needs twelve consecutive quarters filed
Profit, trailing 12 months: —fewer than four consecutive quarters filed
Profit growth, 12 months: —needs eight consecutive quarters filed
Profit 3-year CAGR: —needs twelve consecutive quarters filed

PeersBSE sub-group Biotechnology · F&O stocks with filings on record · industry P/E needs two stocks with trailing profit and a market cap

Stocks in the BSE sub-group Biotechnology with market cap, price to earnings and price to book
Stock	Market cap ₹	P/E	P/B	Close ₹
ANTHEMAnthem Biosciences Limited	48,000 cron 1 Oct	—	16	₹855.75
ADVENZYMESAdvanced Enzyme Technologies Limited	3,000 cron 1 Oct	—	1.8	₹274.25
VIVOBIOTVivo Bio Tech Limited	38 cron 1 Oct	—	—	₹17.15

Shareholding

quarter to 30 Jun · none pledged · NSE filings

Promoters hold 71.4%, foreign portfolio investors 2.6%, mutual funds 11.2% and insurance companies 1.6%, as filed for the quarter to 30 Jun.

71.4%11.2%9.4%

By category, last 2 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file

Shareholding of ANTHEM by category over the last 2 quarters with the change against the previous quarter
Category	30 Jun	31 Mar
Promoters	71.42▼ −3.26 pp	74.68
Foreign portfolio investors	2.57▲ +1.29 pp	1.28
Mutual funds	11.15▲ +1.03 pp	10.12
Insurance companies	1.59▲ +0.66 pp	0.93
Banks and financial institutions	0.74▲ +0.24 pp	0.50
Individual investors	9.45▲ +0.06 pp	9.39
Bodies corporate	0.25▼ −0.01 pp	0.26
Other foreign holders	2.73▼ −0.01 pp	2.74
Others	0.100.00 pp	0.10

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a dividend of ₹2.00 a share, ex-date 25 Jun 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios

Corporate actions of ANTHEM, upcoming first, then the most recent
Ex-date	Action	Amount or ratio	Record date	Source
recent
25 Jun 2026	dividend	₹2.00	26 Jun 2026	BSE

Calendaras notified to the exchange

Next results: —no board meeting notified yet
Dividends in 365 days: ₹4.00a share · ex-dates inside the year
Last dividend: ₹2.00ex-date 25 Jun 2026

Price history

272 sessions on record · to 1 Oct · NSE end of day

ANTHEM is −8.4% over 20 sessions against Nifty's −6.2%, 12% below its 52-week high, realised volatility 27% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions

Returns of the stock and Nifty 50 over six windows, longest first
Window	From ₹	ANTHEM %	Nifty 50 %	Difference pp
250 sessionssince 26 Sept	₹780.87	▲ +9.6%	▼ −9.1%	+19
120 sessionssince 9 Apr	₹720.27	▲ +19%	▼ −5.7%	+25
60 sessionssince 8 Jul	₹748.43	▲ +14%	▼ −6.1%	+20
20 sessionssince 2 Sept	₹934.53	▼ −8.4%	▼ −6.2%	−2.2
5 sessionssince 24 Sept	₹885.59	▼ −3.4%	▼ −2.8%	−0.59
1 sessionsince 30 Sept	₹858.58	▼ −0.33%	▼ −0.88%	+0.55

Averages of the closeclose against each average

5-session average: ₹861.76close −0.70% from it
20-session average: ₹909.74close −5.9% from it
50-session average: ₹878.10close −2.5% from it
200-session average: ₹749.52close +14% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: ₹283.3% of the close
Average day's range, 20: ₹283.2% of the close
Volume against 20 sessions: 0.71×6.5 L vs 8.7 L average

Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell

Realised volatility, 20: 27%≈ ±1.7% a session · moved more than that on 8 of 20
Realised volatility, 60: 28%≈ ±1.8% a session · moved more than that on 16 of 60
Realised volatility, 250: 29%≈ ±1.8% a session · moved more than that on 79 of 250
Beta to Nifty, 60: 0.37moved with Nifty on 29 of 60 sessions
Beta to Nifty, 250: 0.55moved with Nifty on 150 of 250 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 7 up · 13 downof 20
Last 60 sessions: 29 up · 29 downof 58
Last 250 sessions: 116 up · 132 downof 248
Best session, 250: ▲ +6.8%11 Dec
Worst session, 250: ▼ −4.5%15 May

Anthem Biosciences Limited is in 11 NSE indices

all 11 indices

0 bulletins on ANTHEM

The desk has not written about Anthem Biosciences Limited yet. The tape carries every bulletin as it is published.

About Anthem Biosciences Limited

exchange masters as of 18 Sept 2026 · classification by BSE

Company: Anthem Biosciences Limited
Exchange: NSE · BSE 544449, group A
Listed on NSE: 21 Jul 2025
Classification: Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
Index: BSE 500
Face value: ₹2 a share
ISIN: INE0CZ201020
Sessions on record: 272
Price source: NSE UDiFF bhavcopy · end of day · delayed
Filings: NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed: 2 Oct, 02:28 am IST
Bulletins: 0 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.